Shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a clinical-stage biotech, are on the rise today after the company announced results of a recent meeting with the Food and Drug Administration. It looks like the agency isn’t too concerned with mixed data from pivotal trials supporting the company’s first new drug application for Tavalisse, formerly fostamatinib. In response, the stock has risen 33.9% as of 10:58 a.m. EDT during Monday’s session